Insulin Market : Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
Report Highlights
Isulin Market – Scope of Report
TMR’s report on the global insulin market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global insulin market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global insulin market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the insulin market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global insulin market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global insulin market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global insulin market.
The report delves into the competitive landscape of the global insulin market. Key players operating in the global insulin market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global insulin market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market insulin.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
- Company websites, presentations, annual reports, white papers, technical paper, product brochure
- Internal and external proprietary databases and relevant patents
- National government documents, statistical databases, and market reports
- News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
- Industry Sources:
- WorldWideScience.org
- Elsevier, Inc.
- National Institutes of Health (NIH)
- PubMed
- NCBI
- Department of Health Care Service
- Trade Data Sources
- Trade Map
- UN Comtrade
- Trade Atlas
- Company Information
- OneSource Business Browser
- Hoover’s
- Factiva
- Bloomberg
- Mergers & Acquisitions
- Thomson Mergers & Acquisitions
- MergerStat
- Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
- Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
- Helps in validating and strengthening secondary research findings
- Further develops the analysis team’s expertise and market understanding
- Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
- Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
- Purchasing/Sourcing managers, technical personnel, distributors
- Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
- Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
- Advanced Oncotherapy PLC
- Danfysik A/S
- Hitachi, Ltd.
- IBA Worldwide
- Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
- Table 1 : Market Snapshot: Global Insulin Market
- Table 2 : Global Prevalence of Diabetes, by Type
- Table 3 : Global Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
- Table 4 : Global Insulin Market Revenue (US$ Mn), by Source, 2017–2031
- Table 5 : Global Insulin Market Revenue (US$ Mn), by Region, 2017–2031
- Table 6 : North America Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
- Table 7 : Europe Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
- Table 8 : Asia Pacific Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
- Table 9 : Latin America Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
- Table 10 : Middle East & Africa Insulin Market Revenue (US$ Mn), by Mode of Action, 2017–2031
- Figure 1 : Insulin: Market Segmentation
- Figure 2 : Global Insulin Market Revenue (US$ Mn), by Mode of Action, 2021
- Figure 3 : China Insulin Market Revenue (US$ Mn), by Mode of Action, 2021
- Figure 4 : Value Chain: Global Insulin Market
- Figure 5 : Porter’s Five Forces Analysis: Global Insulin Market
- Figure 6 : Market Attractiveness Analysis: Global Insulin Market, by Mode of Action
- Figure 7 : Comparative Analysis: Global Insulin Market Revenue (US$ Mn), by Mode of Action 2021 & 2031
- Figure 8 : Global Short-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 9 : Global Short-Acting Insulin Market Volume (tMU), 2017 – 2031
- Figure 10 : Global Rapid-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 11 : Global Rapid-Acting Insulin Market Volume (tMU), 2017 – 2031
- Figure 12 : Global Afrezza Market Revenue (US$ Mn), 2017 – 2031
- Figure 13 : Global NN1218 Market Revenue (US$ Mn), 2017 – 2031
- Figure 14 : Global Long-Acting Insulin Market Revenue, 2017 – 2031
- Figure 15 : Global Long-Acting Insulin Market Volume (tMU), 2017 – 2031
- Figure 16 : Global LY2605541 Market Revenue (US$ Mn), 2017 – 2031
- Figure 17 : Global LY2963016 Market Revenue (US$ Mn), 2017 – 2031
- Figure 18 : Global MK-1293 Market Revenue (US$ Mn), 2017 – 2031
- Figure 19 : Global U-300 Market Revenue (US$ Mn), 2017 – 2031
- Figure 20 : Global IDegLira Market Revenue (US$ Mn), 2017 – 2031
- Figure 21 : Global Intermediate-acting Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 22 : Global Intermediate-acting Insulin Market Volume (tMU), 2017 – 2031
- Figure 23 : Global Premixed Market Revenue (US$ Mn), 2017 – 2031
- Figure 24 : Global Premixed Insulin Market Volume (tMU), 2017 – 2031
- Figure 25 : Breakdown of insulin-dependent population in China (2009)
- Figure 26 : China Short-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 27 : China Short-Acting Insulin Market Volume (tMU), 2017 – 2031
- Figure 28 : China Rapid-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 29 : China Rapid-Acting Insulin Market Volume (tMU), 2017 – 2031
- Figure 30 : China Long-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 31 : China Long-Acting Insulin Market Volume (tMU), 2017 – 2031
- Figure 32 : China Intermediate-Acting Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 33 : China Intermediate-Acting Insulin Market Volume (tMU), 2017 – 2031
- Figure 34 : China Premixed Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 35 : China Premixed Insulin Market Volume (tMU), 2017 – 2031
- Figure 36 : Global Human Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 37 : Global Human Insulin Market Volume (tMU), 2017 – 2031
- Figure 38 : Global Modern Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 39 : Global Modern Insulin Market Volume (tMU), 2017 – 2031
- Figure 40 : China Human Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 41 : China Human Insulin Market Volume (tMU), 2017 – 2031
- Figure 42 : China Modern Insulin Market Revenue (US$ Mn), 2017 – 2031
- Figure 43 : China Modern Insulin Market Volume (tMU), 2017 – 2031
- Figure 44 : Global Insulin Market Share Analysis, by Key Players, 2021 (%)
- Figure 45 : Eli Lilly and Company: Annual Revenue (US$ Mn), 2017 – 2031
- Figure 46 : Novo Nordisk A/S.: Annual Revenue (US$ Mn), 2017 – 2031
- Figure 47 : Sanofi: Annual Revenue (US$ Mn), 2017 – 2031
- Figure 48 : Shanghai Fosun Pharmaceutical Co., Ltd.
Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.